

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ORBIMED ADVISORS LLC (Last) (First) (Middle) 601 LEXINGTON AVENUE 54TH FLOOR (Street) NEW YORK NY 10022 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Alector, Inc. [ALEC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/11/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/11/2019		C		405,925	A	(1)	405,925	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		C		4,282,288	A	(1)	4,688,213	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		C		2,029,626	A	(1)	6,717,839	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		C		2,280,479	A	(1)	8,998,318	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		C		1,012,282	A	(1)	10,010,600	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		C		266,437	A	(1)	10,277,037	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		P		157,939	A	\$19	10,434,976	I	See footnotes ⁽²⁾⁽³⁾
Common Stock	02/11/2019		C		94,075	A	(1)	94,075	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		C		992,437	A	(1)	1,086,512	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		C		470,374	A	(1)	1,556,886	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		C		528,510	A	(1)	2,085,396	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		C		234,601	A	(1)	2,319,997	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		C		85,295	A	(1)	2,405,292	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		P		50,561	A	\$19	2,455,853	I	See footnotes ⁽³⁾⁽⁴⁾
Common Stock	02/11/2019		P		203,200	A	\$19	203,200	I	See footnotes ⁽³⁾⁽⁵⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-1 Preferred Stock	(I)	02/11/2019		C			405,925	(I)	(I)	Common Stock	405,925	\$0.00	0	I	See footnotes (2)(3)
Series A-1 Preferred Stock	(I)	02/11/2019		C			94,075	(I)	(I)	Common Stock	94,075	\$0.00	0	I	See footnotes (3)(4)
Series A-2 Preferred Stock	(I)	02/11/2019		C			4,282,288	(I)	(I)	Common Stock	4,282,288	\$0.00	0	I	See footnotes (2)(3)
Series A-2 Preferred Stock	(I)	02/11/2019		C			992,437	(I)	(I)	Common Stock	992,437	\$0.00	0	I	See footnotes (3)(4)
Series B Preferred Stock	(I)	02/11/2019		C			2,029,626	(I)	(I)	Common Stock	2,029,626	\$0.00	0	I	See footnotes (2)(3)
Series B Preferred Stock	(I)	02/11/2019		C			470,374	(I)	(I)	Common Stock	470,374	\$0.00	0	I	See footnotes (3)(4)
Series C Preferred Stock	(I)	02/11/2019		C			2,280,479	(I)	(I)	Common Stock	2,280,479	\$0.00	0	I	See footnotes (2)(3)
Series C Preferred Stock	(I)	02/11/2019		C			528,510	(I)	(I)	Common Stock	528,510	\$0.00	0	I	See footnotes (3)(4)
Series D Preferred Stock	(I)	02/11/2019		C			1,012,282	(I)	(I)	Common Stock	1,012,282	\$0.00	0	I	See footnotes (2)(3)
Series D Preferred Stock	(I)	02/11/2019		C			234,601	(I)	(I)	Common Stock	234,601	\$0.00	0	I	See footnotes (3)(4)
Series E Preferred Stock	(I)	02/11/2019		C			266,437	(I)	(I)	Common Stock	266,437	\$0.00	0	I	See footnotes (2)(3)
Series E Preferred Stock	(I)	02/11/2019		C			85,295	(I)	(I)	Common Stock	85,295	\$0.00	0	I	See footnotes (3)(4)

1. Name and Address of Reporting Person*

[ORBIMED ADVISORS LLC](#)

(Last) (First) (Middle)

601 LEXINGTON AVENUE
54TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[OrbiMed Capital GP IV LLC](#)

(Last) (First) (Middle)

601 LEXINGTON AVENUE
54TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person*		
<u>ORBIMED CAPITAL LLC</u>		
(Last)	(First)	(Middle)
601 LEXINGTON AVENUE		
54TH FLOOR		
(Street)		
NEW YORK	NY	10022
(City)		
(State)	(Zip)	

Explanation of Responses:

- Each of the Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- The Shares are held of record by OrbiMed Private Investments IV-AL, LP ("OrbiMed IV-AL"). OrbiMed Capital GP IV LLC ("OrbiMed GP"), is the general partner of OrbiMed IV-AL. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OrbiMed IV-AL and as a result may be deemed to have beneficial ownership over such securities.
- Each of OrbiMed GP, OrbiMed Capital LLC ("OrbiMed Capital") and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 3 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Carl L. Gordon, a member of Advisors, to serve on the Issuer's board of directors.
- The Shares are held of record by OrbiMed Private Investments IV-AL (Feeder), LP ("OrbiMed IV-AL (Feeder)"). OrbiMed GP is the general partner of OrbiMed IV-AL (Feeder). OrbiMed Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OrbiMed IV-AL (Feeder) and as a result may be deemed to have beneficial ownership over such securities.
- The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital, a registered investment adviser under the Investment Advisers Act, acts as the investment advisor to OPM. By virtue of such relationships, OrbiMed Capital may be deemed to have voting and investment power over the securities held by OPM and as a result may be deemed to have beneficial ownership over such securities.

Remarks:

Douglas Coon, attorney-in- 02/11/2019
fact
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.